Interesting Clinical Vignettes: 101 Ice Breakers for Medical Rounds
Total Page:16
File Type:pdf, Size:1020Kb

Load more
Recommended publications
-
Risk Factors and Outcomes of Rapid Correction of Severe Hyponatremia
Article Risk Factors and Outcomes of Rapid Correction of Severe Hyponatremia Jason C. George ,1 Waleed Zafar,2 Ion Dan Bucaloiu,1 and Alex R. Chang 1,2 Abstract Background and objectives Rapid correction of severe hyponatremia can result in serious neurologic complications, including osmotic demyelination. Few data exist on incidence and risk factors of rapid 1Department of correction or osmotic demyelination. Nephrology, Geisinger Medical Center, Design, setting, participants, & measurements In a retrospective cohort of 1490 patients admitted with serum Danville, , Pennsylvania; and sodium 120 mEq/L to seven hospitals in the Geisinger Health System from 2001 to 2017, we examined the 2 incidence and risk factors of rapid correction and osmotic demyelination. Rapid correction was defined as serum Kidney Health . Research Institute, sodium increase of 8 mEq/L at 24 hours. Osmotic demyelination was determined by manual chart review of Geisinger, Danville, all available brain magnetic resonance imaging reports. Pennsylvania Results Mean age was 66 years old (SD=15), 55% were women, and 67% had prior hyponatremia (last outpatient Correspondence: sodium ,135 mEq/L). Median change in serum sodium at 24 hours was 6.8 mEq/L (interquartile range, 3.4–10.2), Dr. Alexander R. Chang, and 606 patients (41%) had rapid correction at 24 hours. Younger age, being a woman, schizophrenia, lower Geisinger Medical , Center, 100 North Charlson comorbidity index, lower presentation serum sodium, and urine sodium 30 mEq/L were associated Academy Avenue, with greater risk of rapid correction. Prior hyponatremia, outpatient aldosterone antagonist use, and treatment at an Danville, PA 17822. academic center were associated with lower risk of rapid correction. -
Ophthalmic Adverse Effects of Nasal Decongestants on an Experimental
A RQUIVOS B RASILEIROS DE ORIGINAL ARTICLE Ophthalmic adverse effects of nasal decongestants on an experimental rat model Efeitos oftálmicos adversos de descongestionantes nasais em modelo experimental com ratos Ayse Ipek Akyuz Unsal1, Yesim Basal2, Serap Birincioglu3, Tolga Kocaturk1, Harun Cakmak1, Alparslan Unsal4, Gizem Cakiroz5, Nüket Eliyatkın6, Ozden Yukselen7, Buket Demirci5 1. Department of Ophthalmology, Medical Faculty, Adnan Menderes University, Aydin, Turkey. 2. Department of Otorhinolaringology, Medical Faculty, Adnan Menderes University, Aydin, Turkey. 3. Department of Pathology, Veterinary Faculty, Adnan Menderes University, Aydin, Turkey. 4. Department of Radiology, Medical Faculty, Adnan Menderes University, Aydin, Turkey. 5. Department of Medical Pharmacology, Medical Faculty, Adnan Menderes University, Aydin, Turkey. 6. Department of Medical Pathology, Medical Faculty, Adnan Menderes University, Aydin, Turkey. 7. Department of Pathology, Aydin State Hospital, Aydin, Turkey. ABSTRACT | Purpose: To investigate the potential effects of cause ophthalmic problems such as dry eyes, corneal edema, chronic exposure to a nasal decongestant and its excipients cataracts, retinal nerve fiber layer, and vascular damage in on ocular tissues using an experimental rat model. Methods: rats. Although these results were obtained from experimental Sixty adult male Wistar rats were randomized into six groups. animals, ophthalmologists should keep in mind the potential The first two groups were control (serum physiologic) and ophthalmic adverse effects of this medicine and/or its excipients Otrivine® groups. The remaining four groups received the and exercise caution with drugs containing xylometazoline, Otrivine excipients xylometazoline, benzalkonium chloride, ethylene diamine tetra acetic acid, benzalkonium chloride and sorbitol, and ethylene diamine tetra acetic acid. Medications sorbitol for patients with underlying ocular problems. -
(CD-P-PH/PHO) Report Classification/Justifica
COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group R01 (Nasal preparations) Table of Contents Page INTRODUCTION 5 DISCLAIMER 7 GLOSSARY OF TERMS USED IN THIS DOCUMENT 8 ACTIVE SUBSTANCES Cyclopentamine (ATC: R01AA02) 10 Ephedrine (ATC: R01AA03) 11 Phenylephrine (ATC: R01AA04) 14 Oxymetazoline (ATC: R01AA05) 16 Tetryzoline (ATC: R01AA06) 19 Xylometazoline (ATC: R01AA07) 20 Naphazoline (ATC: R01AA08) 23 Tramazoline (ATC: R01AA09) 26 Metizoline (ATC: R01AA10) 29 Tuaminoheptane (ATC: R01AA11) 30 Fenoxazoline (ATC: R01AA12) 31 Tymazoline (ATC: R01AA13) 32 Epinephrine (ATC: R01AA14) 33 Indanazoline (ATC: R01AA15) 34 Phenylephrine (ATC: R01AB01) 35 Naphazoline (ATC: R01AB02) 37 Tetryzoline (ATC: R01AB03) 39 Ephedrine (ATC: R01AB05) 40 Xylometazoline (ATC: R01AB06) 41 Oxymetazoline (ATC: R01AB07) 45 Tuaminoheptane (ATC: R01AB08) 46 Cromoglicic Acid (ATC: R01AC01) 49 2 Levocabastine (ATC: R01AC02) 51 Azelastine (ATC: R01AC03) 53 Antazoline (ATC: R01AC04) 56 Spaglumic Acid (ATC: R01AC05) 57 Thonzylamine (ATC: R01AC06) 58 Nedocromil (ATC: R01AC07) 59 Olopatadine (ATC: R01AC08) 60 Cromoglicic Acid, Combinations (ATC: R01AC51) 61 Beclometasone (ATC: R01AD01) 62 Prednisolone (ATC: R01AD02) 66 Dexamethasone (ATC: R01AD03) 67 Flunisolide (ATC: R01AD04) 68 Budesonide (ATC: R01AD05) 69 Betamethasone (ATC: R01AD06) 72 Tixocortol (ATC: R01AD07) 73 Fluticasone (ATC: R01AD08) 74 Mometasone (ATC: R01AD09) 78 Triamcinolone (ATC: R01AD11) 82 -
(12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig. -
Aquagenic Pruritus: First Manifestation of *Corresponding Author Polycythemia Vera Jacek C
DERMATOLOGY ISSN 2473-4799 http://dx.doi.org/10.17140/DRMTOJ-1-102 Open Journal Mini Review Aquagenic Pruritus: First Manifestation of *Corresponding author Polycythemia Vera Jacek C. Szepietowski, MD, PhD Department of Dermatology Venereology and Allergology Wroclaw Medical University Edyta Lelonek, MD; Jacek C. Szepietowski, MD, PhD* Ul. Chalubinskiego 1 50-368 Wroclaw, Poland E-mail: [email protected] Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wroclaw, Poland Volume 1 : Issue 1 Article Ref. #: 1000DRMTOJ1102 ABSTRACT Article History Aquagenic Pruritus (AP) can be a first symptom of systemic disease; especially strong th Received: January 25 , 2016 correlation with myeloproliferative disorders was described. In Polycythemia Vera (PV) pa- th Accepted: February 18 , 2016 tients its prevalence varies from 31% to 69%. In almost half of the cases AP precedes the th Published: February 19 , 2016 diagnosis of PV and has significant influence on sufferers’ quality of life. Due to the lack of the insight in pathogenesis of AP the treatment is still largely experiential. However, the new Citation JAK1/2 inhibitors showed promising results in management of AP among PV patients. Lelonek E, Szepietowski JC. Aqua- genic pruritus: first manifestation of polycythemia vera. Dermatol Open J. KEYWORDS: Aquagenic pruritus; Polycythemia vera; JAK inhibitors. 2016; 1(1): 3-5. doi: 10.17140/DRM- TOJ-1-102 Aquagenic pruritus (AP) is a skin condition characterized by the development of in- tense itching without observable skin lesions and evoked by contact with water at any tempera- ture. Its prevalence varies from 31% to 69% in Polycythemia vera (PV) patients.1,2,3 It has sig- nificant influence on sufferers’ quality of life and can exert a psychological effect to the extent of abandoning bathing or developing phobia to bathing. -
The Itch New Yorker 2008
The New Yorker June 30, 2008 Annals of Medicine The Itch Its mysterious power may be a clue to a new theory about brains and bodies. by Atul Gawande It was still shocking to M. how much a few wrong turns could change your life. She had graduated from Boston College with a degree in psychology, married at twenty-five, and had two children, a son and a daughter. She and her family settled in a town on Massachusetts’ southern shore. She worked for thirteen years in health care, becoming the director of a residence program for men who’d suffered severe head injuries. But she and her husband began fighting. There were betrayals. By the time she was thirty-two, her marriage had disintegrated. In the divorce, she lost possession of their home, and, amid her financial and psychological struggles, she saw that she was losing her children, too. Within a few years, she was drinking. She began dating someone, and they drank together. After a while, he brought some drugs home, and she tried them. The drugs got harder. Eventually, they were doing heroin, which turned out to be readily available from a street dealer a block away from her apartment. One day, she went to see a doctor because she wasn’t feeling well, and learned that she had contracted H.I.V. from a contaminated needle. She had to leave her job. She lost visiting rights with her children. And she developed complications from the H.I.V., including shingles, which caused painful, blistering sores across her scalp and forehead. -
The Late Registrations and Corrections to Greene County Birth Records
Index for Late Registrations and Corrections to Birth Records held at the Greene County Records Center and Archives The late registrations and corrections to Greene County birth records currently held at the Greene County Records Center and Archives were recorded between 1940 and 1991, and include births as early as 1862 and as late as 1989. These records represent the effort of county government to correct the problem of births that had either not been recorded or were not recorded correctly. Often times the applicant needed proof of birth to obtain employment, join the military, or draw on social security benefits. An index of the currently available microfilmed records was prepared in 1989, and some years later, a supplemental index of additional records held by Greene County was prepared. In 2011, several boxes of Probate Court documents containing original applications and backup evidence in support of the late registrations and corrections to the birth records were sorted and processed for archival storage. This new index includes and integrates all the bound and unbound volumes of late registrations and corrections of birth records, and the boxes of additional documents held in the Greene County Archives. The index allows researchers to view a list arranged in alphabetical order by the applicant’s last name. It shows where the official record is (volume and page number) and if there is backup evidence on file (box and file number). A separate listing is arranged alphabetically by mother’s maiden name so that researchers can locate relatives of female relations. Following are listed some of the reasons why researchers should look at the Late Registrations and Corrections to Birth Records: 1. -
N-Arachidonoyl Dopamine Modulates Acute Systemic Inflammation Via Nonhematopoietic TRPV1
N-Arachidonoyl Dopamine Modulates Acute Systemic Inflammation via Nonhematopoietic TRPV1 This information is current as Samira K. Lawton, Fengyun Xu, Alphonso Tran, Erika of October 1, 2021. Wong, Arun Prakash, Mark Schumacher, Judith Hellman and Kevin Wilhelmsen J Immunol 2017; 199:1465-1475; Prepublished online 12 July 2017; doi: 10.4049/jimmunol.1602151 http://www.jimmunol.org/content/199/4/1465 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2017/07/12/jimmunol.160215 Material 1.DCSupplemental http://www.jimmunol.org/ References This article cites 69 articles, 11 of which you can access for free at: http://www.jimmunol.org/content/199/4/1465.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on October 1, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Author Choice Freely available online through The Journal of Immunology Author Choice option Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2017 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology N-Arachidonoyl Dopamine Modulates Acute Systemic Inflammation via Nonhematopoietic TRPV1 Samira K. -
Clear Spring Health HMO Plan Provider Directory
Clear Spring Health HMO Plan Provider Directory This directory is current as of December 1, 2019. This directory provides a list of Clear Spring Health’s current network providers. This directory is for the Illinois Service Area: Boone, Clinton, Cook, Du Page, Kane, Kankakee, La Salle, Macoupin, Madison, Mc Henry, Ogle, St. Clair, Stephenson, Will and Winnebago county. To access Clear Spring Health’s online provider directory, you can visit www.clearspringhealthcare.com. For any questions about the information contained in this directory, please call our Member Service Department at 877-384-1241, we are open 8:00 am to 8:00 pm Md on ay – Friday from April 1 – September 30 and 8:00 am to 8:00 pm Monday – Sunday from October 1 – March 31. TTY users should call 711. Out-of-network/non-contracted providers are under no obligation to treat Clear Spring Health members, except in emergency situations. Please call our Member Service number or see your Evidence of Coverage for more information, including the cost-sharing that applies to out-of- network services. Our plan has people and free interpreter services available to answer questions from disabled and non-English speaking members. We can also give you information in Braille, in large print, or other alternate formats at no cost if you need it. We are required to give you information about the plan’s benefits in a format that is accessible and appropriate for you. To get information from us in a way that works for you, please call Member Services or contact Office for Civil Rights. -
Psychiatric Comorbidities in Non-Psychogenic Chronic Itch, a US
1/4 CLINICAL REPORT Psychiatric Comorbidities in Non-psychogenic Chronic Itch, a US- DV based Study 1 1 1 1 1 2 cta Rachel Shireen GOLPANIAN , Zoe LIPMAN , Kayla FOURZALI , Emilie FOWLER , Leigh NATTKEMPER , Yiong Huak CHAN and Gil YOSIPOVITCH1 1 2 A Department of Dermatology and Cutaneous Surgery, and Itch Center University of Miami Miller School of Medicine, Miami, USA, and Clinical Trials and Epidemiology Research Unit, Singapore Research suggests that itch and psychiatric diseases SIGNIFICANCE are intimately related. In efforts to examine the preva- lence of psychiatric diagnoses in patients with chronic The primary aim of this study was to examine the preva- itch not due to psychogenic causes, we conducted a lence of psychiatric diagnoses in patients with chronic itch retrospective chart review of 502 adult patients diag- that is not due to psychogenic causes. The secondary aim nosed with chronic itch in an outpatient dermatology of this study was to determine whether psychiatric diagno- clinic specializing in itch and assessed these patients ses have any correlation to specific itch characteristics such enereologica for a co-existing psychiatric disease. Psychiatric di- as itch intensity, or if there are any psychiatric-specific di- V sease was identified and recorded based on ICD-10 seases this patient population is more prone to. This infor- codes made at any point in time which were recor- mation will not only allow us to better understand the po- ded in the patient’s electronic medical chart, which tential factors underlying the presentation of chronic itch, includes all medical department visits at the Univer- but also allow us to provide these patients with more holis- ermato- sity of Miami. -
Diagnosis and Management of Hyponatremia Melinda Johnson, MD, FHM, FACP, FPHM Associate Professor, Internal Medicine University of Iowa Hospitals and Clinics
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Iowa Research Online UPDATED Diagnosis and Management of Hyponatremia Melinda Johnson, MD, FHM, FACP, FPHM Associate Professor, Internal Medicine University of Iowa Hospitals and Clinics Hyponatremia Low serum Normal or high osmolality serum <280 mOsm/kg osmolality Pseudo- Euvolemic Hypervolemic Redistributive Hypovolemic hyponatremia Una <20 mEq/L Una >20 mEq/L Una >20, Uosm Una >20, Uosm Una<20 mEq/L Una>20 mEq/L Uosm >300 Uosm <100 Hyperlipidemia Hyperglycemia <100 mOsm/kg >300 mOsm/kg mOsm/kg mOsm/kg Mannitol, Drug effect maltose, Advanced renal Hyper- Dehydration (thiazides, ACE- Beer potomania SIADH CHF sucrose, glycine, failure proteinemia I) or sorbitol administration Salt-wasting Psychogenic Diarrhea Postoperative Liver disease Biliary Azotemia nephropathies polydipsia Mineralocorti- Hypo- Nephrotic Alcohol Vomiting coid deficiency thyroidism syndrome intoxication Drug effect Cerebral (thiazides, ACE- sodium-wasting I) Adrenocorticotr opin deficiency Hyponatremia Serum sodium concentration <135 mEq/L Severe hyponatremia <120 mEq/L Disorder of water, not salt Occurs in ~15% of all hospital inpatients Increased morbidity and mortality Symptoms depend on rate of fall 1 Total Body Water Intracellular Interstitial Intravascular •Water load, causing decreased serum Sosm osmolality •Leading to suppressed ADH ADH (vasopressin) •Leading to water excretion in dilute Uosm urine (decreased Uosm) Impaired Renal Water Excretion 1. Inability to -
European Guideline Chronic Pruritus Final Version
EDF-Guidelines for Chronic Pruritus In cooperation with the European Academy of Dermatology and Venereology (EADV) and the Union Européenne des Médecins Spécialistes (UEMS) E Weisshaar1, JC Szepietowski2, U Darsow3, L Misery4, J Wallengren5, T Mettang6, U Gieler7, T Lotti8, J Lambert9, P Maisel10, M Streit11, M Greaves12, A Carmichael13, E Tschachler14, J Ring3, S Ständer15 University Hospital Heidelberg, Clinical Social Medicine, Environmental and Occupational Dermatology, Germany1, Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Poland2, Department of Dermatology and Allergy Biederstein, Technical University Munich, Germany3, Department of Dermatology, University Hospital Brest, France4, Department of Dermatology, Lund University, Sweden5, German Clinic for Diagnostics, Nephrology, Wiesbaden, Germany6, Department of Psychosomatic Dermatology, Clinic for Psychosomatic Medicine, University of Giessen, Germany7, Department of Dermatology, University of Florence, Italy8, Department of Dermatology, University of Antwerpen, Belgium9, Department of General Medicine, University Hospital Muenster, Germany10, Department of Dermatology, Kantonsspital Aarau, Switzerland11, Department of Dermatology, St. Thomas Hospital Lambeth, London, UK12, Department of Dermatology, James Cook University Hospital Middlesbrough, UK13, Department of Dermatology, Medical University Vienna, Austria14, Department of Dermatology, Competence Center for Pruritus, University Hospital Muenster, Germany15 Corresponding author: Elke Weisshaar